Overview Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer Status: Recruiting Trial end date: 2025-06-27 Target enrollment: Participant gender: Summary This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer. Phase: Phase 1 Details Lead Sponsor: Arvinas Androgen Receptor, Inc.